Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Fund Letter | Nathan Fredrick, CFARiverwater Partners Small Cap Strategy | PharmaceuticalsPharmaceuticals | Long PBH (Prestige Consumer Healthcare Inc.) Prestige Consumer Healthcare (PBH): We initiated a position in Prestige Consumer Healthcare, which owns a portfolio of niche over-the-counter health brands, including Dramamine, Clear Eyes, Breathe Right, and Chloraseptic. We view the... | BULL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Cameron McKendryTurtle Creek | Food ProductsFood Products | Turtle Creek Fund - PBH.TO Another large detractor from our performance in 2026 is Premium Brands, a company that we have owned for over 20 years (at various weightings) and is currently one of our largest holdings. Premium Brands is... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Luke CummingsHarvest Lane Asset Management | Casinos & GamingHotels, Restaurants & Leisure | Long PBH.AX (Pointsbet) This reticence was definitely the case with Pointsbet (ASX:PBH), which was a long, but very rewarding arbitrage trade in 2025 (along with New World Resources it has been the standout merger arbitrage trade of 2025 to date). We are generally... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Steve JohnsonForager Australian Shares Fund | Casinos & GamingHotels, Restaurants & Leisure | Long PBH.AX (PointsBet Holdings Limited) Betting company Pointsbet (PBH) announced a takeover offer from Tokyo-listed MIXI (TSE:2121) in February. Pointsbet's board is... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Brandes Investment Partners, L.P.Brandes Small Cap Value Fund | PharmaceuticalsPharmaceuticals | Brandes Small Cap Value Fund 2025 Q3 (PBH) Brandes re-entered Prestige Consumer Healthcare after share weakness created a value opportunity. Prestige owns market-leading... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Andrew J. FlemingHeartland Value Plus Fund | PharmaceuticalsPharmaceuticals | Heartland Value Plus Fund 2025 Q3 (PBH) Prestige Consumer Healthcare (PBH) — the company behind familiar over-the-counter medical products such as Dramamine, Luden's cough drops, and Clear Eyes eye drops — was the biggest detractor to our Strategy's performance during the quarter. That's in part... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | John W. RogersAriel Appreciation Fund | PharmaceuticalsPharmaceuticals | Ariel Appreciation Fund 2025 Q3 (PBH) Prestige Consumer Healthcare Inc. (PBH), a marketer and distributor of over-the-counter pharmaceutical products. The company has... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Ariel Investments, LLCAriel Focus Fund | PharmaceuticalsPharmaceuticals | Ariel Focus Fund 2025 Q3 (PBH) New holding and distributor of over-the-counter pharmaceutical drugs and products, Prestige Consumer Healthcare Inc. (PBH), also declined following mixed earnings results and a downward revision to full-year guidance. Sales were impacted... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.